文献速递脑血管病外科神经重症

美国EC-IC搭桥术后再入院:全国发生率、原因、危险因素与医院手术量的影响

Readmission following extracranial-intracranial bypass surgery in the United States: nationwide rates, causes, risk factors, and volume-driven outcomes.
PubMed 文献 · J Neurosurg · 2020-11-06

该研究基于2010-2014年美国全国再入院数据库,纳入2500例因烟雾病、症状性颅内动脉粥样硬化性疾病或未破裂动脉瘤行EC-IC搭桥的患者,分析再入院率、原因、危险因素及医院手术量的影响。结果显示30天和90天再入院率分别为7.5%和14.0%,再入院主要由合并症、社会经济状况及低手术量中心驱动,高手术量中心治疗与更低的并发症和再入院率相关。

要点

  • EC-IC搭桥术后30天和90天再入院率分别为7.5%和14.0%。
  • 再入院原因包括新发卒中(2.5%)、伤口并发症(2.5%)、移植物失败(1.5%)和其他感染(1.3%)。
  • 高手术量中心治疗与更低的非常规出院、90天内缺血性卒中及30/90天再入院率显著相关。

核心结论

  • EC-IC搭桥术后再入院率与其他常见颅脑手术相当,主要由合并症、社会经济状况及低手术量中心驱动。
  • 围手术期并发症(卒中、移植物失败、伤口并发症)发生率与既往临床系列一致。
  • 集中化治疗可能显著降低围手术期并发症、再入院率和医院资源利用。

研究设计与样本

  • 回顾性队列研究,查询美国全国再入院数据库(NRD)2010-2014年数据。
  • 纳入2500例因烟雾病(63.1%)、症状性颅内动脉粥样硬化性疾病(24.5%)或未破裂动脉瘤(12.4%)行EC-IC搭桥的患者,平均年龄41岁。
  • 高手术量中心定义为每年完成10例及以上搭桥手术。
  • 采用多变量分析识别再入院的预测因素并研究高手术量中心对质量结局的影响。

主要发现

  • 30天和90天再入院率分别为7.5%和14.0%。
  • 再入院原因包括新发卒中(2.5%)、伤口并发症(2.5%)、移植物失败(1.5%)和其他感染(1.3%)。
  • 多变量分析中,再入院的危险因素包括医疗补助/自费(OR 1.6,95%CI 1.1-2.4,对比私人保险)、合并症评分(每增加一种合并症OR 1.2,95%CI 1.1-1.4)和非高手术量中心治疗(OR 1.9,95%CI 1.1-3.0)。
  • 高手术量中心治疗(17%的患者)与非常规出院率(13.4% vs 26.7%,p=0.004)、90天内缺血性卒中(0.8% vs 2.9%,p=0.03)、30天再入院(3.9% vs 8.2%,p=0.03)和90天再入院(8.6% vs 15.2%,p=0.01)显著降低相关,多变量分析证实了这些发现。

关键数值与推荐

  • 高手术量中心定义为每年完成10例及以上EC-IC搭桥手术。
  • 再入院危险因素的多变量OR值:医疗补助/自费OR 1.6(95%CI 1.1-2.4),合并症评分每增加一种OR 1.2(95%CI 1.1-1.4),非高手术量中心OR 1.9(95%CI 1.1-3.0)。
  • 高手术量中心与非高手术量中心的结局比较:非常规出院13.4% vs 26.7%(p=0.004),90天内缺血性卒中0.8% vs 2.9%(p=0.03),30天再入院3.9% vs 8.2%(p=0.03),90天再入院8.6% vs 15.2%(p=0.01)。

临床怎么用

  • 对于因烟雾病、症状性颅内动脉粥样硬化性疾病或未破裂动脉瘤考虑EC-IC搭桥的患者,可优先转诊至高手术量中心以降低围手术期并发症和再入院风险。
  • 对医疗补助/自费及合并症负担高的患者应加强围手术期管理和出院后随访,以降低再入院风险。
  • 临床实践中应关注术后新发卒中、伤口并发症和移植物失败等再入院主要原因的预防和早期识别。

局限性

  • 研究为回顾性数据库分析,可能存在编码偏倚和未测量混杂因素。
  • 高手术量中心的定义(每年10例及以上)为作者设定,可能影响结果解释。
  • 再入院原因分类基于行政数据库编码,可能存在误分类。
  • 研究仅纳入2010-2014年数据,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Extracranial-intracranial (EC-IC) bypass surgery remains an important treatment option for patients with moyamoya disease (MMD), intracranial arteriosclerotic disease (ICAD) with symptomatic stenosis despite the best medical management, and complex aneurysms. The therapeutic benefit of cerebral bypass surgery depends on optimal patient selection and the minimization of periprocedural complications. The nationwide burden of readmissions and associated complications following EC-IC bypass surgery has not been previously described. Therefore, the authors sought to analyze a nationwide database to describe the national rates, causes, risk factors, complications, and morbidity associated with readmission following EC-IC bypass surgery for MMD, ICAD, and aneurysms. METHODS: The Nationwide Readmissions Database (NRD) was queried for the years 2010-2014 to identify patients who had undergone EC-IC bypass for MMD, medically failed symptomatic ICAD, or unruptured aneurysms. Predictor variables included demographics, preexisting comorbidities, indication for surgery, and hospital bypass case volume. A high-volume center (HVC) was defined as one that performed 10 or more cases/year. Outcome variables included perioperative stroke, discharge disposition, length of stay, total hospital costs, and readmission (30 days, 90 days). Multivariable analysis was used to identify predictors of readmission and to study the effect of treatment at HVCs on quality outcomes. RESULTS: In total, 2500 patients with a mean age of 41 years were treated with EC-IC bypass surgery for MMD (63.1%), ICAD (24.5%), or unruptured aneurysms (12.4%). The 30- and 90-day readmission rates were 7.5% and 14.0%, respectively. Causes of readmission included new stroke (2.5%), wound complications (2.5%), graft failure (1.5%), and other infection (1.3%). In the multivariable analysis, risk factors for readmission included Medicaid/self-pay (OR 1.6, 95% CI 1.1-2.4, vs private insurance), comorbidity score (OR 1.2, 95% CI 1.1-1.4, per additional comorbidity), and treatment at a non-HVC (OR 1.9, 95% CI 1.1-3.0). Treatment at an HVC (17% of patients) was associated with significantly lower rates of nonroutine discharge dispositions (13.4% vs 26.7%, p = 0.004), ischemic stroke within 90 days (0.8% vs 2.9%, p = 0.03), 30-day readmission (3.9% vs 8.2%, p = 0.03), and 90-day readmission (8.6% vs 15.2%, p = 0.01). These findings were confirmed in a multivariable analysis. The authors estimate that centralization to HVCs may result in 333 fewer nonroutine discharges (50% reduction), 12,000 fewer hospital days (44% reduction), 165 fewer readmissions (43%), and a cost savings of $15.3 million (11% reduction). CONCLUSIONS: Readmission rates for patients after EC-IC bypass are comparable with those after other common cranial procedures and are primarily driven by preexisting comorbidities, socioeconomic status, and treatment at low-volume centers. Periprocedural complications, including stroke, graft failure, and wound complications, occurred at the expected rates, consistent with those in prior clinical series. The centralization of care may significantly reduce perioperative complications, readmissions, and hospital resource utilization.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Rumalla K, Srinivasan VM, Gaddis M, et al. Readmission following extracranial-intracranial bypass surgery in the United States: nationwide rates, causes, risk factors, and volume-driven outcomes. J Neurosurg. 2020. PMID: 33157529. doi:10.3171/2020.6.JNS202117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。